MEDP
Medpace Holdings, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Dec 4 Medpace, Inc. v. Agenus Inc. et al.
- Jan 15 ▼ Gilbert Cisneros sold $15,001 - $50,000, last disclosed Feb 16
- Feb 26 ▲ David Taylor bought $1,001 - $15,000, last disclosed Mar 9
- May 15 ▲ David Taylor bought $1,001 - $15,000, last disclosed May 29
- Jul 27 to Jul 28 ▼ 2 days of insider sells: $8.8M by 2 insiders, avg $600.22
- Aug 7 to Aug 27 ▼ 12 days of insider sells: $73.8M by 6 insiders, avg $612.06
- Sep 15 to Sep 30 ▼ 11 days of insider sells: $125.9M by 1 insider, avg $624.08
- Sep 30 ▲ 3 funds open new positions (13F)
- Sep 30 ▲ UBS upgrades
- Oct 21 ▲ Medpace reported Q3 2026 revenue of $716.0M (+8.5% YoY) and GAAP dil…
- Oct 21 ▲ Earnings: MEDP Q3 2026 Earnings: EPS $4.84 (+7.0% vs est)
- Oct 26 to Oct 29 ▼ 3 days of insider sells: $14.4M by 2 insiders, avg $677.76
Signal stack
Where each data set points today.
- InsidersBEARISH
8 insiders sold $222.9M.
- InstitutionsBULLISH
Q3 2026: 38 added (3 new), 20 trimmed or exited. Largest new: Qube Research & Technologies $99.5M, Cibc Bancorp Usa $19.2M.
- AnalystsMIXED
7 of 20 rate it Buy or better. Median target $675.00 (+4%).
- Short sellersSTEADY
Short interest −14.2% to 1.38M shares. 3.5 days to cover, ≈5.0% of shares.
- TrendUPTREND
3% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 31.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| WASATCH ADVISORS LP | TRIM | $290.8M |
| Aberdeen Group plc | DOUBLED | $192.5M |
| FMR LLC | DOUBLED | $127.4M |
| CITIGROUP INC | ADD | $112.7M |
| Qube Research & Technologies Ltd | NEW | $99.5M |
| UBS Group AG | TRIM | $72.5M |
| FIRST TRUST ADVISORS LP | DOUBLED | $64.7M |
| Artemis Investment Management LLP | DOUBLED | $59.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
20 analystsPrice is inside the target range. Median implies +4%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 26, 2026 | BMO Capital MAINTAIN | Market Perform |
| Oct 23, 2026 | UBS MAINTAIN | Neutral |
| Oct 23, 2026 | Truist Securities MAINTAIN | Hold |
| Oct 23, 2026 | Barclays MAINTAIN | Equal-Weight |
| Oct 23, 2026 | TD Cowen MAINTAIN | Hold |
| Oct 7, 2026 | Mizuho MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
EWALD STEPHEN P General Counsel & Corp. Secy. Oct 29, 2026 | SELL | $859.0K |
BURWIG SUSAN E Exec. VP, Operations Oct 27, 2026 | SELL | $2.7M |
BURWIG SUSAN E Exec. VP, Operations Oct 26, 2026 | EXERCISE | $54.7K |
BURWIG SUSAN E Exec. VP, Operations Oct 26, 2026 | SELL | $10.9M |
BURWIG SUSAN E Exec. VP, Operations Oct 21, 2026 | EXERCISE | $450.2K |
BURWIG SUSAN E Exec. VP, Operations Oct 12, 2026 | EXERCISE | $500.2K |
BURWIG SUSAN E Exec. VP, Operations Oct 7, 2026 | EXERCISE | $333.5K |
Kraft Robert O. Director Sep 30, 2026 | EXERCISE | 32 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
24 filings · 3 bullish · 4 bearish · 1 mixed · 16 neutral- BEARISH SC 13G/ANov 16, 2026
T. Rowe Price Associates filed an amended Schedule 13G disclosing a 4.1% passive stake in Medpace Holdings, down from the 5.00% stake reported by AQR Capital Management three days earlier. The reduction below 5% signals a passive exit by a major institutional holder, though the filing provides no…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13GNov 13, 2026
AQR Capital Management disclosed a 5.00% passive stake in Medpace Holdings via a new Schedule 13G…
AQR's new 5% passive stake signals conviction from a quantitative manager, but as a 13G filer there is no activist intent. Monitor future 13G amendments for stake increases or a conversion to 13D…
- BEARISH CLUSTERNov 2, 2026
Two Medpace insiders (General Counsel and EVP of Operations) sold a combined $3.53M in open-market…
The sales are small relative to market cap but notable for being open-market, non-10b5-1, and clustered shortly after earnings. Monitor for additional insider selling in the coming weeks; the prior…
- NEUTRAL 144Oct 29, 2026
Stephen P. Ewald, an officer of Medpace Holdings, Inc., filed a Form 144 notice of intent to sell…
The filing is a routine advance notice of a small insider sale. Monitor for the actual sale on Form 4 to confirm execution, but no material impact on the stock is expected from this transaction alone.
All MEDP filing & press-release reports (24)
- SC 13G/A reportNov 16, 2026
- SC 13G reportNov 13, 2026
- CLUSTER reportNov 2, 2026
- 144 reportOct 29, 2026
- 144 reportOct 27, 2026
- 144 reportOct 26, 2026
- INST-CLUSTER reportOct 23, 2026
- 8-K reportOct 21, 2026
- SC 13D/A reportSep 28, 2026
- CLUSTER reportAug 31, 2026
- CLUSTER reportAug 28, 2026
- CLUSTER reportAug 27, 2026
- CLUSTER reportAug 25, 2026
- CLUSTER reportAug 24, 2026
- CLUSTER reportAug 21, 2026
- 144 reportAug 19, 2026
- CLUSTER reportAug 14, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportJul 29, 2026
- 144 reportJul 27, 2026
- COURT-RULING reportDec 4, 2025
- 8-K reportApr 22, 2026
- DEFA14A reportApr 1, 2026